Vyleesi Cost in Oregon 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Vyleesi Is and Why Oregon Residents Are Looking for Cost Information

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist approved by the FDA on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works differently from flibanserin (Addyi): patients self-inject 1.75 mg subcutaneously roughly 45 minutes before anticipated sexual activity, rather than taking a daily oral pill. That on-demand model appeals to many women, but the price tag stops most of them short.

Oregon has a relatively strong public insurance program through the Oregon Health Plan (OHP), and the state permits 503A compounding pharmacies to prepare bremelanotide. Both facts matter when mapping out your options.

How Bremelanotide Works

Bremelanotide binds melanocortin receptors (MC1R and MC4R) in the central nervous system, modulating dopamine and other neurotransmitter pathways linked to sexual motivation. The mechanism is distinct from hormonal therapies and from PDE5 inhibitors used off-label in men.

The FDA label notes that the drug should not be used more than once within 24 hours, and no more than about eight times per month based on clinical trial dosing patterns. Nausea (affecting roughly 40% of users in trials) and transient blood-pressure increases are the most common adverse effects.

The RECONNECT Trial: Clinical Evidence at a Glance

The key RECONNECT program, published in Obstetrics and Gynecology in 2019 (N=1,247 premenopausal women with HSDD), showed statistically significant improvements in satisfying sexual events and desire scores versus placebo. RECONNECT provided the core efficacy data supporting FDA approval. Women receiving bremelanotide reported a mean increase of 0.5 satisfying sexual events per month versus 0.2 for placebo (P<0.001) and a clinically meaningful reduction in distress related to low desire.

No Oregon-specific efficacy subgroup exists, but the enrolled population reflected the general premenopausal U.S. Demographic.

Vyleesi Cash Price in Oregon in 2026

The manufacturer list price for Vyleesi is $1,200 per month as of 2026, and Oregon retail pharmacies mirror that figure almost exactly for uninsured or out-of-pocket payers. Each carton contains four auto-injectors (a one-month supply at realistic usage rates), priced around $300 per injector.

Why the Cash Price Is So High

Palatin Technologies holds the U.S. Rights to bremelanotide. With a small indicated population (premenopausal women with HSDD), development and post-market costs are spread across relatively few prescriptions nationally. The result is a per-unit cost that sits far above most chronic-condition medications.

No generic bremelanotide has received FDA approval as of early 2026. That means Oregon residents without coverage or savings programs face the full $1,200 outlay.

GoodRx and Pharmacy Coupon Programs

Retail coupon aggregators such as GoodRx do not reliably reduce Vyleesi below $1,000 to $1,100 in Oregon because the drug has no generic competitors. Coupons help more on off-patent generics. For Vyleesi, the manufacturer's own savings program (discussed below) typically delivers a larger reduction for commercially insured patients.

Oregon Medicaid (OHP) Coverage for Vyleesi

Oregon Medicaid, administered through the Oregon Health Plan (OHP), covers Vyleesi for HSDD in premenopausal women, but requires prior authorization (PA). This is the single most important coverage fact for low-income Oregon residents.

Prior Authorization Requirements on OHP

To get PA approved on OHP, a prescriber generally must document:

• A confirmed diagnosis of HSDD (not attributable to another medical condition, relationship problem, medication side effect, or substance use).
• That the patient is premenopausal.
• That an adequate assessment was completed, often referencing validated tools such as the Female Sexual Distress Scale (FSDS) or the Female Sexual Function Index (FSFI).
• That other identifiable causes of reduced desire have been addressed or ruled out.

OHP managed care organizations (MCOs) in Oregon, including PacificSource Community Solutions, Trillium Community Health Plan, and Jackson Care Connect, each administer their own PA processes. Timelines vary from 3 to 14 business days. Work with your prescriber's office to submit clinical notes alongside the PA request.

What Happens If PA Is Denied

If OHP denies a PA for Vyleesi, you have the right to request a formal appeal. Oregon's Office of Administrative Hearings handles Medicaid appeals. You can also ask your prescriber to submit a peer-to-peer review with the MCO's medical director. Documented FSDS scores and a clear HSDD diagnosis strengthen the appeal.

Compounded Bremelanotide in Oregon: Legality and Cost

Compounded bremelanotide from a licensed 503A pharmacy is legal in Oregon in 2026. That distinction matters enormously for cost. Where brand Vyleesi runs $1,200 per month, compounded bremelanotide from an Oregon-licensed or Oregon-shipping 503A compounding pharmacy costs approximately $140 per month.

503A vs. 503B: What Oregon Residents Need to Know

The U.S. Compounding framework distinguishes 503A pharmacies (patient-specific compounding, licensed under state boards) from 503B outsourcing facilities (bulk compounders registered with the FDA). Most compounded bremelanotide prescribed to individual Oregon patients comes from 503A pharmacies operating under the Oregon State Board of Pharmacy.

Because bremelanotide is not on the FDA's "essentially a copy" list (as of early 2026) and is not a commercially available product easily substituted by the compounded version without patient-specific justification, 503A pharmacies can legally prepare it for individual patients with a valid prescription from a licensed provider. Check the FDA's current compounding guidance for updates, since this regulatory area shifts.

Quality Considerations for Compounded Bremelanotide

Compounded preparations are not FDA-approved. Purity, sterility, and potency depend on the individual pharmacy's practices. When choosing a 503A pharmacy for compounded bremelanotide in Oregon:

• Confirm the pharmacy holds a current Oregon State Board of Pharmacy license.
• Ask whether the pharmacy uses USP 797 sterile compounding standards (required for injectable preparations).
• Request a certificate of analysis (COA) from a third-party lab showing confirmed bremelanotide concentration and sterility.

A price difference of over $1,000 per month is real. So is the quality-assurance difference. These are not equivalent products from a regulatory standpoint, and your prescriber should factor that into the recommendation.

The HealthRX clinical team uses a three-step triage for Oregon patients asking about compounded bremelanotide: (1) confirm HSDD diagnosis with FSDS-R score at or above 11, indicating clinically meaningful distress; (2) screen for contraindications including cardiovascular disease and use of naltrexone or opioids; (3) route to compounded 503A only after documenting that the prescriber has reviewed the pharmacy's USP 797 compliance and COA. This framework is applied across all HealthRX Oregon telehealth consultations involving bremelanotide.

Insurance Coverage for Vyleesi in Oregon

Commercial Insurance Plans

Commercial insurance coverage for Vyleesi in Oregon is inconsistent. Some plans place it on Tier 3 or Tier 4 formularies with copays ranging from $50 to $300 per fill after deductible. Others exclude it outright as a "sexual dysfunction" exclusion category. Oregon does not mandate commercial plan coverage of HSDD medications, so coverage depends entirely on your employer's plan design or the plan you purchased through the Oregon Health Insurance Marketplace.

Call the member-services number on your insurance card and ask specifically: "Is bremelanotide (brand name Vyleesi, NDC 47335-204-41) covered on my formulary, and if so, what tier?"

The Palatin Technologies Savings Card

For commercially insured patients who do have some formulary coverage, Palatin Technologies offers a savings card program. Eligible patients may pay as little as $0 copay per fill, with a maximum annual benefit capped at a specified dollar amount. The program excludes patients enrolled in federal or state government insurance programs (Medicare, Medicaid, TRICARE). Oregon OHP enrollees are therefore ineligible.

To enroll, visit the Vyleesi manufacturer website or ask your pharmacist. The savings card is processed at the point of sale. Most Oregon retail pharmacies, including major chains, can run it alongside your insurance claim.

Medicare Coverage

Medicare Part D does not cover drugs approved solely for sexual dysfunction, per a statutory exclusion. Oregon Medicare beneficiaries have no pathway to Vyleesi coverage under Part D as of 2026. This exclusion is written into federal law (42 U.S.C. 1395w-102(e)(2)), not a plan-level decision.

Telehealth Prescribing of Vyleesi in Oregon

Oregon law allows telehealth prescribing of Vyleesi by licensed providers who establish a valid prescriber-patient relationship, which can occur via synchronous audio-video visit. Bremelanotide is not a controlled substance (it is Schedule V-exempt as a non-opioid, non-stimulant), so Oregon does not impose the controlled-substance telehealth restrictions that apply to, say, testosterone or stimulants.

What to Expect at a Telehealth Appointment

A typical telehealth visit for HSDD and Vyleesi in Oregon covers:

• Review of current medications (naltrexone and opioid analgesics are contraindications; use with antihypertensives requires monitoring because bremelanotide transiently raises blood pressure and lowers heart rate).
• Administration of validated questionnaires such as the FSFI or FSDS-R to document baseline severity.
• Discussion of alternative or adjunctive treatments, including flibanserin (Addyi), pelvic floor physical therapy referral, or hormone evaluation if perimenopause is suspected.
• Injection training, since bremelanotide is self-administered subcutaneously in the abdomen or thigh.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "Hypoactive sexual desire disorder is the most common form of female sexual dysfunction and can significantly impair quality of life; a biopsychosocial approach to assessment and treatment is recommended." ACOG Practice Bulletin No. 213 is a useful reference for providers documenting HSDD for PA purposes.

Telehealth Platforms Serving Oregon

Multiple telehealth platforms ship to Oregon and can prescribe Vyleesi or compounded bremelanotide. HealthRX offers licensed providers in Oregon who conduct synchronous video consultations and can route prescriptions to either a retail pharmacy (for brand Vyleesi) or a vetted 503A compounding pharmacy (for compounded bremelanotide).

Comparing Your Oregon Cost Pathways Side by Side

| Pathway | Estimated Monthly Cost | Coverage / Eligibility Notes | |---|---|---| | Brand Vyleesi, no insurance | ~$1,200 | Any Oregon resident with prescription | | Brand Vyleesi, commercial insurance (Tier 3) | $50 to $300 copay | Varies by plan; PA may be required | | Brand Vyleesi + Palatin savings card | $0 copay (cap applies) | Commercially insured only; no Medicaid | | Oregon OHP (Medicaid) | $0 to small copay | Requires PA; managed via MCO | | Compounded bremelanotide, 503A | ~$140 | 503A pharmacy; not FDA-approved |

Costs above reflect 2026 averages. Oregon pharmacy dispensing fees ($3 to $12 per fill) may apply on top of drug cost.

Clinical Context: Who Is Vyleesi For?

Vyleesi is FDA-approved specifically for generalized, acquired HSDD in premenopausal women. "Generalized" means low desire occurs across partners and situations. "Acquired" means it developed after a period of normal desire. The drug is not indicated for:

• Postmenopausal women (evidence base does not cover this population).
• Men (no approved indication).
• Women whose low desire is attributable to a relationship problem alone, a concurrent psychiatric condition, or a medication side effect that has not been addressed.

The Endocrine Society's clinical practice guideline on female sexual dysfunction (2019) recommends shared decision-making between clinician and patient when selecting pharmacotherapy for HSDD. Endocrine Society Guideline states that treatment selection should account for patient preference, adverse-effect profile, and cost.

RECONNECT enrolled women aged 22 to 50 with a mean FSDS-R score of 24.2 at baseline, indicating moderate to severe distress. RECONNECT full data showed that roughly 25% of bremelanotide-treated women achieved a minimally clinically important difference on the FSFI desire domain versus 17% on placebo.

Practical Steps for Oregon Residents Ready to Start

Getting Vyleesi or compounded bremelanotide in Oregon involves a predictable sequence:

1. Schedule a telehealth or in-person visit with an OB-GYN, women's health NP, or sexual medicine specialist licensed in Oregon. Bring a list of current medications and be prepared to complete an FSFI or FSDS-R questionnaire.

2. Determine your insurance situation before the visit. Call your insurer to check formulary status. If you are on OHP, tell your provider so they can initiate the PA at the same time as the prescription.

3. Choose brand vs. Compounded based on cost and quality preferences. If compounded, ask your provider to send the prescription to a 503A pharmacy that holds current Oregon licensure and can provide a COA.

4. Enroll in the savings card if you have commercial insurance coverage and the brand drug is accessible.

5. Learn the injection technique before the first planned use. Bremelanotide is injected subcutaneously 45 minutes before sexual activity. Do not inject intravenously. The auto-injector is single-use.

The transient nausea that affects a substantial portion of users typically peaks 30 to 60 minutes after injection and resolves within two to four hours. Taking the injection with a light snack reduces severity in some patients. Blood pressure may rise 6 mmHg systolic on average and then returns to baseline within 12 hours, per the FDA prescribing information.